Congenital Heart Disease: Comprehensive Disease-Characteristics Report

Executive summary

Congenital heart disease (CHD) is an umbrella term for structurally or functionally important cardiovascular malformations arising during embryonic development and present at birth, although mild lesions may not be recognized until childhood or adulthood. It is not one molecular disease: lesions range from small septal defects to tetralogy of Fallot (TOF), transposition of the great arteries (TGA), hypoplastic left-heart syndrome (HLHS), and heterotaxy. Contemporary studies generally place prevalence near 1% of live births; broader definitions that include bicuspid aortic valve and very small defects produce estimates approaching 1–2%. Genetic or recognized environmental causes are found in only a minority of all cases, but diagnostic yield rises markedly in severe, syndromic, or extracardiac-malformation cohorts. In a 2024 neonatal intensive-care cohort, a molecular/cytogenetic diagnosis was established in 17% (32/188) of infants. (helm2021geneticevaluationof pages 1-2, peterlin2024thegeneticarchitecture pages 10-12)

CHD begins prenatally but is usually a lifelong condition rather than a lesion “cured” by surgery. Improved fetal diagnosis, neonatal surgery, catheter intervention, and longitudinal care have shifted much of the burden toward adult heart failure, arrhythmia, pulmonary vascular disease, reintervention, neurodevelopmental disability, and psychosocial morbidity. Sudden cardiac death (SCD) is reported at 0.28–2.7% per year in CHD cohorts and 0.9–1.5% per year after TOF in the reviewed literature, accounting for as many as 25% of CHD deaths in some populations. (salzillo2024cardiovasculardiseasesin pages 10-11)

The following table provides an ontology-oriented synopsis.

Table: This table condenses the conversation’s established congenital heart disease facts into ontology-ready domains for a knowledge base. It highlights identifiers, phenotypes, genes, pathways, anatomy, diagnostics, treatments, and key evidence caveats with citeable context IDs.

1. Disease information

Definition and classification

CHD comprises abnormalities of cardiac chambers, septa, valves, coronary arteries, aorta, great arteries, venous connections, and/or conduction-related anatomy caused by abnormal cardiovascular morphogenesis. Clinically useful groupings include:

• Septal lesions: ventricular septal defect (VSD), atrial septal defect, atrioventricular septal defect.
• Left-sided obstruction: bicuspid aortic valve, valvar/subvalvar aortic stenosis, coarctation, interrupted aortic arch, HLHS.
• Right-sided obstruction: pulmonary stenosis/atresia and tricuspid atresia.
• Conotruncal defects: TOF, truncus arteriosus, TGA, double-outlet right ventricle.
• Anomalous connections: total/partial anomalous pulmonary venous connection.
• Single-ventricle and laterality disorders: unbalanced atrioventricular canal, heterotaxy, and other functionally univentricular hearts.

Identifiers and synonyms

• MONDO: MONDO:0005453, congenital heart disease. Related umbrella term: MONDO:0019512, congenital heart malformation; syndromic CHD: MONDO:0100614.
• MeSH: Heart Defects, Congenital.
• ICD-10-CM: principally Q20–Q28; Q20–Q26 cover congenital malformations of cardiac chambers/connections, septa, valves, great arteries, and great veins.
• ICD-11: lesion-specific entities reside under congenital anomalies of the circulatory system; a single code should not replace lesion-level coding.
• OMIM/Orphanet: no single OMIM entry adequately represents all CHD. OMIM and Orphanet are most appropriately attached to the causal syndrome or lesion–gene disorder, such as 22q11.2 deletion syndrome, Holt–Oram syndrome, or NKX2-5-related disease.
• Synonyms: congenital heart defect, congenital cardiac defect, congenital cardiovascular malformation, congenital heart anomaly, congenital cardiac malformation.

The definition, ontology identifiers, and pooled epidemiology are aggregated disease-level knowledge. Patient-specific lesion, imaging, procedure, and genotype data are ordinarily derived from EHRs, registries, or cohorts and should remain provenance-linked rather than being treated as universal disease facts.

2. Etiology, risk, protection, and gene–environment interaction

Genetic causal factors

CHD has a mixed architecture: aneuploidies and pathogenic copy-number variants (CNVs), highly penetrant single-gene variants, incompletely penetrant inherited variants, de novo variants, oligogenic combinations, and common polygenic susceptibility all occur. Earlier severe-infant cohorts attributed approximately 8–10% to aneuploidy, 3–5% to single-gene disease, and a variable 3–25% to pathogenic CNVs, depending strongly on ascertainment and technology. (helm2021geneticevaluationof pages 1-2)

Major chromosomal/syndromic contributors include trisomies 21, 18, and 13; monosomy X; 22q11.2 deletion; Williams–Beuren syndrome; CHARGE; and RASopathies such as Noonan syndrome. Trisomy 21 is especially associated with atrioventricular septal defects; 22q11.2 deletion/TBX1 with conotruncal and aortic-arch defects; Turner syndrome with bicuspid aortic valve and coarctation; and Williams syndrome with supravalvar aortic stenosis. A 2024 NICU study found 22q11.2 deletion and CHARGE most often, followed by Noonan and Williams syndromes. (salzillo2024cardiovasculardiseasesin pages 13-15, peterlin2024thegeneticarchitecture pages 10-12)

High-priority developmental genes include NKX2-5, GATA4, GATA6, TBX1, TBX5, TBX20, NOTCH1, JAG1, KMT2D, CHD7, ELN, PTPN11, RAF1, ZIC3, NODAL, GDF1, MMP21, MYH6, ACTC1, TAB2, TFAP2B, and GJA1. Open Targets ranks NKX2-5 and GATA4 among the strongest general CHD associations and also supports TBX20, GDF1, MYH6, TFAP2B, TAB2, NODAL, MMP21, GJA1, and TBX1. These associations are lesion- and syndrome-dependent and should not be interpreted as a validated universal “CHD panel.” (OpenTargets Search: congenital heart disease)

Variant classes include germline missense, nonsense, frameshift, splice, regulatory, and structural variants. Pathogenic alleles are usually rare or absent in population databases; no meaningful single carrier frequency exists for heterogeneous CHD. Classification should follow ACMG/AMP criteria using segregation, de novo status, population frequency, functional evidence, and phenotype specificity. A 2024 familial study reported heterozygous BMP4 NM_001202.6:c.318T>G, p.(Tyr106*), cosegregating with CHD; mutant BMP4 failed to activate NKX2-5 and TBX20 reporter expression. This is promising single-family evidence, not justification for treating all rare BMP4 variants as pathogenic. (salzillo2024cardiovasculardiseasesin pages 13-15)

Environmental and maternal factors

An umbrella review covering 56 systematic reviews, 369 meta-analyses, and 949 component studies found the strongest reported non-genetic associations for maternal pregestational/gestational diabetes, obesity—particularly moderate or severe obesity—gestational hypertension, antidepressant exposure including SSRIs/SNRIs, harmful chemicals, renovation materials, noise exposure, and reproductive/family-history variables. Only 16% of the included systematic reviews were rated “moderate” by AMSTAR2, so association does not necessarily establish causation. (zubrzycki2024cardiacdevelopmentand pages 25-26)

Other recognized or suspected risks include maternal phenylketonuria, rubella infection, retinoic acid, valproate, lithium for selected lesions, smoking, alcohol, air pollution, fever, advanced parental age, assisted reproduction, and occupational solvent/pesticide exposure. Absolute risk generally remains low for any single exposure, and confounding by indication is important for medication studies.

Protective factors and prevention-relevant modifiers

Periconceptional folic acid/multivitamin use is associated with lower risk in several observational syntheses, but effect size varies by lesion and study design. The evidence supports adequate folate for general congenital-anomaly prevention, not a guarantee against CHD. Glycemic optimization before conception and during early pregnancy is one of the clearest modifiable strategies for women with diabetes. Avoidance of rubella through pre-pregnancy immunization, teratogen review, smoking/alcohol avoidance, healthy weight, and treatment of maternal phenylketonuria are also rational primary-prevention measures. (zubrzycki2024cardiacdevelopmentand pages 25-26)

No reproducible “protective CHD allele” is established for routine clinical use. Modifier alleles and background polygenic burden probably influence penetrance and severity, but remain research-level.

Gene–environment interaction

The biologically plausible model is that maternal metabolic or toxic exposures alter oxidative stress, one-carbon metabolism, chromatin state, signaling, or neural-crest/second-heart-field development in an embryo whose genetic background changes susceptibility. Folate-pathway variants and maternal folate are a frequently studied example, but robust lesion-specific G×E estimates are limited. Thus, exposure history and molecular diagnosis should be represented as interacting evidence rather than mutually exclusive causes.

3. Phenotypes

Frequencies cannot be assigned across “CHD” as a whole because each lesion defines a different denominator. Severity ranges from clinically silent to lethal without neonatal intervention. Quality-of-life impact reflects not only anatomy but also surgeries, exercise capacity, neurodevelopment, mental health, socioeconomic access, and transition to adult care.

4. Genetic and molecular information

Inheritance and penetrance

Inheritance may be autosomal dominant, autosomal recessive, X-linked, chromosomal, or multifactorial. Dominant developmental-gene disorders often show incomplete penetrance and variable expressivity; recessive laterality/cilia disorders are enriched in consanguineous populations; ZIC3 causes X-linked heterotaxy in some families. De novo variants are important in severe sporadic/syndromic CHD. Parental and germline mosaicism can produce recurrence despite negative parental blood testing. Anticipation is not a general feature. Founder variants exist for particular syndromes/populations, but there is no single CHD founder allele or carrier frequency.

Functional mechanisms

• Transcription-factor haploinsufficiency: NKX2-5, GATA4/6, TBX5/20, and TBX1 disturb specification, chamber formation, septation, or conduction-system development.
• Signaling defects: NOTCH/JAG1, BMP/TGF-β, WNT, RAS–MAPK, and NODAL pathways alter progenitor fate, endocardial cushion formation, outflow tract patterning, valve development, or left–right asymmetry.
• Chromatin/epigenetic regulation: CHD7, KMT2D, and other chromatin regulators change developmental gene accessibility; pathogenic mechanisms are usually germline and developmental rather than somatic.
• Contractile/cytoskeletal dysfunction: MYH6, ACTC1, MYH7, MYBPC3, and TNNT2 can connect structural malformation with myocardial dysfunction.
• Cilia/laterality: ZIC3, NODAL, GDF1, MMP21, and ciliary genes disrupt left–right organizer function and produce heterotaxy.

Routine databases may label variants pathogenic, likely pathogenic, VUS, likely benign, or benign. VUS should not guide irreversible surgery, prenatal decision-making, or predictive testing. Somatic variants are not a principal established cause of ordinary CHD, although somatic mosaicism is biologically plausible and increasingly detectable with deep sequencing.

Chromosomal abnormalities

Clinically important abnormalities include whole-chromosome aneuploidies and recurrent CNVs such as 22q11.2 deletion and 7q11.23 deletion. Structural rearrangements, mosaic aneuploidy, and nonrecurrent CNVs also occur. CMA therefore remains valuable even when examination suggests isolated CHD: one infant cohort found diagnostic CMA in 6.5% of apparently isolated cases. (helm2021geneticevaluationof pages 1-2)

5. Environmental information

The most consequential exposure window is early organogenesis, approximately gestational weeks 3–8. Maternal diabetes can expose the embryo to hyperglycemia, oxidative stress, and altered signaling; retinoids and antiepileptics can perturb transcriptional programs; rubella can produce a congenital infection syndrome with patent ductus arteriosus and pulmonary-artery stenosis. Air pollution, solvents, pesticides, smoking, and alcohol have epidemiologic associations of varying consistency. (zubrzycki2024cardiacdevelopmentand pages 25-26)

CHD is not infectious or transmissible. Rubella is an upstream teratogenic infection, not an infection acquired from the affected infant. Exercise by the mother is not established as a lesion-specific protective intervention, although general preconception health is beneficial.

6. Mechanism and pathophysiology

Upstream developmental chain

1. Trigger: pathogenic variant/CNV/aneuploidy, maternal exposure, or combined susceptibility.
2. Developmental perturbation: altered chromatin, transcription-factor dosage, WNT/BMP/NOTCH/TGF-β/RAS–MAPK/NODAL signaling, metabolism, or ciliary left–right patterning.
3. Cellular effect: abnormal proliferation, migration, differentiation, epithelial-to-mesenchymal transition, neural-crest contribution, myocardialization, or apoptosis.
4. Morphogenetic failure: defective looping, septation, endocardial cushions, valves, outflow tract, arch, venous return, or ventricular growth.
5. Clinical physiology: left-to-right shunt, obstruction, mixing/cyanosis, regurgitation, or single-ventricle circulation.
6. Downstream remodeling: pressure/volume load, hypoxemia, neurohormonal activation, endothelial dysfunction, pulmonary vascular remodeling, hypertrophy, fibrosis, arrhythmia, and heart failure.

Suggested GO terms include heart development GO:0007507, heart looping GO:0001947, cardiac septum morphogenesis GO:0060916, Notch signaling GO:0007219, BMP signaling GO:0030509, Wnt signaling GO:0016055, epithelial-to-mesenchymal transition GO:0001837, neural-crest-cell migration GO:0001755, mitochondrial respiratory-chain complex assembly GO:0033108, and response to oxidative stress GO:0006979.

Relevant Cell Ontology concepts include cardiomyocyte CL:0000746, endothelial cell CL:0000115, fibroblast CL:0000057, neural crest cell CL:0000333/ontology release-dependent, endocardial cell, epicardial cell CL:0002494, and cardiac progenitor cell.

Molecular profiling and advanced technologies

A 2024 single-cell/machine-learning analysis used 21,034 fibroblasts, 73,296 cardiomyocytes, and 35,673 endothelial cells. Candidate cell-type signatures included FOXO3 in fibroblasts; TMTC1, ART3, ARHGAP24, SHROOM3, and XIST in cardiomyocyte analyses; and COL25A1, NFIB, and KLF7 in endothelial analyses. These are computational biomarkers requiring independent biological and prospective clinical validation. (ma2024machinelearningin pages 2-3, ma2024machinelearningin pages 21-23)

Patient-specific iPSC cardiomyocytes are being used to model TOF, single-ventricle disease, and HLHS. HLHS models have shown mitochondrial dysfunction, oxidative stress, abnormal unfolded-protein responses, sarcomere defects, and impaired contractility. CRISPR correction of MYH6-R443P rescued sarcomeric and contractile phenotypes in vitro; sildenafil and tauroursodeoxycholic acid emerged as experimental pathway-directed candidates, not established HLHS treatments. (pushpan2024ipscderivedcardiomyocytesas pages 10-11)

Perioperative metabolomics is another emerging application. A 2024 systematic review included seven studies and 509 children and found associations of amino-acid/fatty-acid-related profiles with mortality, acute kidney injury, and neurologic outcomes, but heterogeneity and small samples preclude clinical biomarker adoption. One included neonatal dataset sampled 149 infants around cardiopulmonary bypass. (meggiolaro2024metabolomicprofilingof pages 4-5)

7. Anatomical structures affected

The primary organ is the heart (UBERON:0000948), including atria, ventricles, interatrial/interventricular septa, endocardial cushions, valves, myocardium, endocardium, epicardium, and conduction system. Great-vessel sites include the aorta UBERON:0000947, pulmonary trunk/arteries, arterial duct, aortic arch, systemic veins, and pulmonary veins. Laterality can be normal, mirror-imaged, or discordant/asymmetric in heterotaxy.

Secondary organ injury involves lungs/pulmonary vasculature, liver and lymphatics after Fontan circulation, kidneys after low output or bypass, brain through fetal dysmaturation/hypoxemia/embolism, and intestine through low perfusion. Subcellular compartments include nucleus/chromatin, primary cilia, mitochondria, sarcomere, intercellular junctions, and endoplasmic reticulum. Chromosomal disease can additionally involve immune, endocrine, craniofacial, renal, skeletal, auditory, and neurodevelopmental systems. (salzillo2024cardiovasculardiseasesin pages 13-15, pushpan2024ipscderivedcardiomyocytesas pages 10-11)

8. Temporal development and natural history

CHD originates in embryogenesis and is therefore congenital, even when diagnosis is delayed. Critical duct-dependent lesions often deteriorate acutely when the ductus arteriosus closes during the first days of life. Large shunts tend to produce heart failure over weeks as pulmonary vascular resistance falls. Small septal defects may remain stable or close spontaneously.

Surgery usually repairs or palliates anatomy but does not remove lifelong risk. Intermediate and late stages may include residual shunts/obstruction, valve dysfunction, ventricular failure, aortopathy, pulmonary hypertension, arrhythmia, endocarditis, thrombosis, protein-losing enteropathy, plastic bronchitis, Fontan-associated liver disease, and transplant consideration. There is no general spontaneous remission category; lesion-specific closure of small defects is the main exception. Critical intervention windows include prenatal recognition, delivery planning, prostaglandin initiation before ductal closure, neonatal repair/palliation, and structured adolescent transition.

9. Inheritance and population epidemiology

CHD affects approximately 1% of live-born infants in commonly used definitions; ascertainment, inclusion of mild defects, prenatal loss, and access to echocardiography drive geographic differences. (helm2021geneticevaluationof pages 1-2, peterlin2024thegeneticarchitecture pages 10-12)

Sex distribution is lesion-specific rather than uniformly male or female: left-sided obstructive lesions and TGA are more common in males, while atrial septal defects and patent ductus arteriosus are often more common in females. Ethnic/racial differences partly reflect genetic background but also maternal risk, prenatal detection, termination practices, socioeconomic conditions, referral, and registry completeness. Resource-limited regions experience disproportionate preventable mortality because fetal diagnosis, pediatric surgery, catheter care, and lifelong specialist follow-up are less available. (salzillo2024cardiovasculardiseasesin pages 15-16, salzillo2024cardiovasculardiseasesin pages 13-15)

Empiric recurrence after an isolated nonsyndromic CHD is usually a few percent but varies by lesion and family history; a known Mendelian or chromosomal diagnosis replaces the empirical estimate with disorder-specific counseling. Incomplete penetrance and variable expressivity are common. Consanguinity increases recessive forms, particularly laterality/cilia disorders.

10. Diagnostics

Clinical and imaging approach

• Prenatal: screening obstetric ultrasound with outflow-tract views; fetal echocardiography for abnormal screening, family history, maternal diabetes/teratogen exposure, increased nuchal translucency, fetal genetic abnormality, or extracardiac malformation. Prenatal CMA and sequencing are considered when CHD is detected, particularly with extracardiac findings.
• Newborn: physical examination, pre-/postductal oxygen saturation, pulse assessment, blood pressure when indicated, and universal pulse-oximetry screening for critical CHD where implemented. A normal screen does not exclude coarctation or noncyanotic disease.
• Definitive anatomy: transthoracic echocardiography is first line; transesophageal/intracardiac echo supports interventions.
• CMR: quantifies chamber volumes, ventricular function, flow, shunts, fibrosis, edema, and complex postoperative anatomy without ionizing radiation. Limitations include expertise, scan time, device compatibility, breath holding, and anesthesia in younger children.
• CT/catheterization: CT offers rapid high-resolution vascular/coronary anatomy at the cost of radiation/contrast; catheterization supplies invasive hemodynamics and permits intervention.
• Functional surveillance: ECG, ambulatory monitoring, exercise testing, cardiopulmonary exercise testing, and laboratory markers such as BNP/NT-proBNP in selected heart-failure contexts.

Prenatal screening, fetal echocardiography, genomic testing, postoperative monitoring, and molecular autopsy are emphasized for chromosomal/sudden-death-risk CHD. (salzillo2024cardiovasculardiseasesin pages 13-15)

Genetic testing

A practical sequence is: detailed three-generation pedigree and dysmorphology/extracardiac assessment; rapid aneuploidy testing or karyotype when suspected; CMA for severe/syndromic CHD; then phenotype-guided panel or preferably trio WES/WGS when CMA is nondiagnostic. FISH remains useful for targeted confirmation/family studies but should not substitute for genome-wide CNV testing. Mitochondrial testing is indicated only where phenotype supports it; repeat-expansion testing is not routine CHD testing.

In 440 infants, CMA yield was 14.6% and combined testing yield 17%; LV outflow-tract obstruction had 15.8% yield among apparently isolated cases. In a 2024 cohort of 188 neonates, 17% received one of 22 genetic diagnoses, CMA yield was 10.1%, and VUS were found in 4.8%. Reported WGS yield reached 27% in a cited implementation, with management changed in 62% of diagnosed cases. (helm2021geneticevaluationof pages 1-2, peterlin2024thegeneticarchitecture pages 10-12)

RNA-seq, methylation episignatures, optical genome mapping, long-read sequencing, proteomics, and metabolomics remain second-line or research tools. They are useful for splice confirmation, cryptic structural variation, syndrome resolution, and biomarker discovery, but are not substitutes for anatomic diagnosis.

Differential diagnosis

Important alternatives include persistent pulmonary hypertension of the newborn, neonatal sepsis, respiratory disease, cardiomyopathy, arrhythmia/channelopathy without malformation, innocent murmur, acquired valvular disease, and extracardiac causes of cyanosis or failure to thrive. Echocardiographic anatomy distinguishes these from structural CHD.

11. Outcomes and prognosis

Prognosis is lesion-, era-, center-, genotype-, comorbidity-, and access-dependent; one pooled “five-year survival” is misleading. Small isolated defects can confer normal lifespan. Critical/single-ventricle disease has substantial neonatal risk and chronic morbidity despite successful palliation. Trisomies 13 and 18 generally carry worse early prognosis than trisomy 21, while outcomes within every genetic category remain heterogeneous. (salzillo2024cardiovasculardiseasesin pages 15-16)

Important adverse prognostic factors include complex anatomy, single-ventricle physiology, ventricular dysfunction, pulmonary hypertension, cyanosis, arrhythmia, residual hemodynamic lesions, multiple sternotomies, extracardiac/genetic disease, prematurity/low birth weight, renal injury, socioeconomic disadvantage, and interrupted specialist care. In CHD cohorts, SCD incidence of 0.28–2.7% annually and TOF estimates of 0.9–1.5% annually underscore the need for lifelong rhythm and hemodynamic surveillance. (salzillo2024cardiovasculardiseasesin pages 10-11)

Morbidity includes exercise limitation, heart failure, stroke/thromboembolism, endocarditis, repeat procedures, pregnancy risk, neurodevelopmental disability, anxiety/depression, educational/employment effects, and caregiver burden. Quality of life can remain good despite complex anatomy but is generally worse with functional limitation, repeated intervention, pain/trauma, and poor access. Lesion-specific PROMIS, PedsQL, SF-36, EQ-5D, and disease-specific adult-CHD instruments should be stored with age and anatomy rather than pooled indiscriminately.

12. Treatment

Lesion-directed intervention

• Septal defects/ductus: observation when small; transcatheter closure or surgical repair for significant shunt, chamber dilation, symptoms, or selected endocarditis risk.
• Valve/outflow obstruction: balloon valvuloplasty, catheter stenting, surgical valvotomy/reconstruction, or valve replacement depending on anatomy.
• Coarctation: surgery or catheter stent, with lifelong hypertension/aortic surveillance.
• TGA: prostaglandin E1 to maintain ductal patency, balloon atrial septostomy when mixing is inadequate, and neonatal arterial-switch operation.
• TOF: complete repair, later pulmonary-valve replacement when indicated, and rhythm surveillance.
• HLHS/single ventricle: prostaglandin stabilization followed by staged Norwood, bidirectional Glenn, and Fontan palliation, hybrid strategies, transplant, or individualized comfort care.

Suggested NCIt concepts include Cardiac Surgical Procedure, Cardiac Catheterization, Balloon Valvuloplasty, Norwood Procedure, Glenn Procedure, Fontan Procedure, Heart Transplantation, and Implantable Cardioverter Defibrillator. Current modalities span open surgery, catheterization, balloon valvuloplasty, staged single-ventricle operations, drug therapy, ICDs, and transplant. (salzillo2024cardiovasculardiseasesin pages 13-15, ma2024machinelearningin pages 2-3)

Pharmacotherapy and supportive care

Drugs generally manage physiology or complications rather than correcting the malformation: prostaglandin E1 for duct-dependent circulation; diuretics and selected ACE inhibitors/beta blockers for heart failure; pulmonary vasodilators for carefully characterized pulmonary vascular disease; antiarrhythmics and anticoagulants/antiplatelets for indicated rhythm/thrombotic risks; antibiotics for established infection and narrowly defined endocarditis prophylaxis. No universal CHD pharmacogenomic algorithm exists.

Nutritional support, developmental surveillance, neuropsychology, exercise prescription/cardiac rehabilitation, dental care, reproductive counseling, pregnancy management, and structured transition to adult congenital cardiology are integral. Physical activity should be individualized; blanket restriction is often harmful.

Experimental and precision approaches

CRISPR correction, gene replacement, RNA therapeutics, regenerative cell therapy, engineered valves, and tissue-engineered conduits remain experimental for most CHD. iPSC rescue of MYH6-associated dysfunction is proof of mechanism, not clinical gene therapy. (pushpan2024ipscderivedcardiomyocytesas pages 10-11)

Examples of current real-world research include the recruiting lifecycle registry NCT06611787, designed for approximately 100,000 patients across more than 20 hospitals with fetal-to-adult data, biospecimens, reoperation, and long-term survival outcomes; the Swiss adult registry NCT02258724; fetal complex-CHD multi-omics NCT06705543; and personalized non-invasive electrocardiographic imaging NCT07425132. The Beijing registry began recruitment in February 2024 and plans extended longitudinal follow-up. (NCT06611787 chunk 1)

13. Prevention

• Primary: preconception diabetes and phenylketonuria control; healthy maternal weight; folic acid according to public-health guidance; rubella vaccination before pregnancy; medication/teratogen review; avoidance of smoking, alcohol, and illicit drugs; occupational/environmental protection. These measures reduce risk but cannot prevent most CHD. (zubrzycki2024cardiacdevelopmentand pages 25-26)
• Secondary: prenatal ultrasound/fetal echocardiography, prenatal genetics, planned delivery at an appropriate center, newborn examination and pulse oximetry, prompt echocardiography, and cascade testing when a familial diagnosis is found.
• Tertiary: timely repair/palliation, residual-lesion and arrhythmia surveillance, vaccination, dental hygiene, selective endocarditis prophylaxis, exercise/weight management, neurodevelopmental services, contraception/pregnancy counseling, and uninterrupted congenital-cardiology follow-up.

Preimplantation or prenatal genetic testing is feasible when a pathogenic familial variant or chromosomal rearrangement is known. It is much less informative for unexplained multifactorial CHD. Genetic counseling must discuss variable expressivity, incomplete penetrance, residual risk, and the difference between detecting a genotype and predicting lesion severity.

14. Other species and natural disease

Naturally occurring septal defects, patent ductus arteriosus, pulmonic stenosis, subaortic stenosis, TOF, valve dysplasia, and vascular-ring anomalies occur in dogs, cats, horses, cattle, and other vertebrates. Domestic dog (NCBI Taxon 9615) and cat (9685) are the principal companion-animal contexts; breed predispositions suggest heritable susceptibility, but breed–variant claims should be taken from OMIA/VBO records for the precise lesion rather than generalized to CHD.

Veterinary CHD is non-zoonotic and not cross-species transmissible. Comparative relevance derives from conserved cardiac development, hemodynamics, and orthologs—not infection. Spontaneous animal cases can better model anatomical scale and catheter/surgical procedures than rodents, although breed structure and incomplete genotyping limit direct human inference.

15. Model organisms and experimental systems

• Mouse, Mus musculus (Taxon 10090): knockout/knock-in, conditional, and chromosomal-synteny models reproduce septation, valve, outflow-tract, arch, and laterality defects. A 2024 Down-syndrome model showed that three copies of Dyrk1a impaired cardiomyocyte proliferation and mitochondrial respiration; restoring two copies rescued septation, and prenatal DYRK1A inhibition partially reversed transcriptional abnormalities. This is strong model-organism mechanistic evidence but not yet a safe prenatal human therapy.
• Zebrafish, Danio rerio (Taxon 7955): rapid, transparent embryos and efficient CRISPR permit high-throughput assessment of looping, chamber patterning, contractility, and laterality. Limitations include a two-chamber heart and important differences in septation and placental/maternal physiology.
• Human iPSC cardiomyocytes: preserve patient genotype and permit isogenic CRISPR controls, functional phenotyping, and drug screening. They incompletely reproduce mature myocardium, multicellular anatomy, loading, circulation, and whole-organ morphogenesis. Recent CHD models have combined WES, RNA-seq, and single-cell transcriptomics. (pushpan2024ipscderivedcardiomyocytesas pages 10-11)
• Cardiac organoids and engineered tissues: model interactions among myocardium, endocardium, epicardium, vascular cells, and foregut-like tissues. They are promising for developmental toxicology and spatial multi-omics but currently lack complete four-chamber anatomy, mature conduction, physiologic perfusion, and maternal–placental context.
• Chick and Xenopus: valuable for neural-crest migration, looping, microsurgery, and lineage tracing; translation is constrained by species-specific anatomy.

Recent developments and expert interpretation, 2023–2024

1. Broader genomic testing: recent neonatal data support CMA plus sequencing rather than restricting testing to obviously dysmorphic infants. Expert interpretation is that phenotypic examination alone lacks sufficient sensitivity; nevertheless, the lower yield in isolated CHD means counseling should anticipate nondiagnostic and VUS results. (helm2021geneticevaluationof pages 1-2, peterlin2024thegeneticarchitecture pages 10-12)
2. Cell-resolved molecular maps: single-cell sequencing and machine learning now resolve cardiomyocyte, endothelial, and fibroblast signatures, but retrospective classification performance is not equivalent to a clinically validated biomarker. (ma2024machinelearningin pages 2-3, ma2024machinelearningin pages 21-23)
3. Patient-specific disease modeling: iPSC/CRISPR systems can test causality and rescue individual cellular defects. Their immediate application is mechanism and drug prioritization rather than clinical genome editing. (pushpan2024ipscderivedcardiomyocytesas pages 10-11)
4. Metabolomic risk stratification: perioperative signatures may help forecast kidney, neurologic, and mortality outcomes, but current evidence is too heterogeneous and small for routine use. (meggiolaro2024metabolomicprofilingof pages 4-5)
5. Lifecycle registries and digital surveillance: very large registries, wearables, and non-invasive electrical imaging aim to connect fetal anatomy, genotype, operations, adult complications, and patient-reported outcomes. Equity and international standardization remain major implementation challenges. (salzillo2024cardiovasculardiseasesin pages 15-16, NCT06611787 chunk 1)

Selected exact abstract statements and source metadata

• Helm et al., Genes, published August 2021, DOI: https://doi.org/10.3390/genes12081244: “Cumulative evidence provides a rationale for comprehensive, standardized genetic evaluation in infants with severe CHDs regardless of lesion or extracardiac anomalies.” The study reported CMA yield of 14.6% and overall genetic-testing yield of 17%. (helm2021geneticevaluationof pages 1-2)
• Peterlin et al., Life, published September 2024, DOI: https://doi.org/10.3390/life14091118: “We established the genetic diagnosis of 22 distinct syndromes in 17% (32/188) of neonates.” (peterlin2024thegeneticarchitecture pages 10-12)
• Ma et al., Life, published August 2024, DOI: https://doi.org/10.3390/life14081032: the study states that it analyzed “21,034 cardiac fibroblasts, 73,296 cardiomyocytes, and 35,673 endothelial cells,” illustrating the scale of emerging cell-resolved CHD profiling. (ma2024machinelearningin pages 2-3, ma2024machinelearningin pages 21-23)
• Meggiolaro et al., Frontiers in Cardiovascular Medicine, published November 2024, DOI: https://doi.org/10.3389/fcvm.2024.1491046: “Seven studies involving 509 children … were included,” and the authors judged the findings promising but limited by heterogeneous designs and small samples. (meggiolaro2024metabolomicprofilingof pages 4-5)

PMIDs were not consistently exposed in the retrieved records; DOI URLs are therefore supplied for the principal recent sources rather than risking incorrect PMID assignment. Evidence labels should distinguish human cohorts/registries, systematic reviews, computational single-cell analyses, in-vitro iPSC experiments, and model-organism studies. The principal knowledge-base caveat is that CHD is a heterogeneous umbrella category: lesion-, genotype-, age-, and procedure-specific facts should be stored separately whenever possible.

References

1. (helm2021geneticevaluationof pages 1-2): Benjamin M. Helm, Benjamin J. Landis, and Stephanie M. Ware. Genetic evaluation of inpatient neonatal and infantile congenital heart defects: new findings and review of the literature. Genes, 12:1244, Aug 2021. URL: https://doi.org/10.3390/genes12081244, doi:10.3390/genes12081244. This article has 35 citations.

2. (peterlin2024thegeneticarchitecture pages 10-12): Ana Peterlin, Sara Bertok, Karin Writzl, Luca Lovrečić, Aleš Maver, Borut Peterlin, Maruša Debeljak, and Gregor Nosan. The genetic architecture of congenital heart disease in neonatal intensive care unit patients—the experience of university medical centre, ljubljana. Life, 14:1118, Sep 2024. URL: https://doi.org/10.3390/life14091118, doi:10.3390/life14091118. This article has 3 citations.

3. (salzillo2024cardiovasculardiseasesin pages 10-11): Cecilia Salzillo, Marco La Verde, Amalia Imparato, Rossella Molitierno, Stefano Lucà, Francesca Pagliuca, and Andrea Marzullo. Cardiovascular diseases in public health: chromosomal abnormalities in congenital heart disease causing sudden cardiac death in children. Medicina, 60:1976, Dec 2024. URL: https://doi.org/10.3390/medicina60121976, doi:10.3390/medicina60121976. This article has 15 citations.

4. (ma2024machinelearningin pages 2-3): Qinglan Ma, Yu-Hang Zhang, Wei Guo, Kaiyan Feng, Tao Huang, and Yu-Dong Cai. Machine learning in identifying marker genes for congenital heart diseases of different cardiac cell types. Life, 14:1032, Aug 2024. URL: https://doi.org/10.3390/life14081032, doi:10.3390/life14081032. This article has 9 citations.

5. (OpenTargets Search: congenital heart disease): Open Targets Query (congenital heart disease, 33 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (salzillo2024cardiovasculardiseasesin pages 13-15): Cecilia Salzillo, Marco La Verde, Amalia Imparato, Rossella Molitierno, Stefano Lucà, Francesca Pagliuca, and Andrea Marzullo. Cardiovascular diseases in public health: chromosomal abnormalities in congenital heart disease causing sudden cardiac death in children. Medicina, 60:1976, Dec 2024. URL: https://doi.org/10.3390/medicina60121976, doi:10.3390/medicina60121976. This article has 15 citations.

7. (zubrzycki2024cardiacdevelopmentand pages 25-26): Marek Zubrzycki, Rene Schramm, Angelika Costard-Jäckle, Jochen Grohmann, Jan F. Gummert, and Maria Zubrzycka. Cardiac development and factors influencing the development of congenital heart defects (chds): part i. International Journal of Molecular Sciences, 25:7117, Jun 2024. URL: https://doi.org/10.3390/ijms25137117, doi:10.3390/ijms25137117. This article has 42 citations.

8. (ma2024machinelearningin pages 21-23): Qinglan Ma, Yu-Hang Zhang, Wei Guo, Kaiyan Feng, Tao Huang, and Yu-Dong Cai. Machine learning in identifying marker genes for congenital heart diseases of different cardiac cell types. Life, 14:1032, Aug 2024. URL: https://doi.org/10.3390/life14081032, doi:10.3390/life14081032. This article has 9 citations.

9. (pushpan2024ipscderivedcardiomyocytesas pages 10-11): Chithra K. Pushpan and Subramanyan Ram Kumar. Ipsc-derived cardiomyocytes as a disease model to understand the biology of congenital heart defects. Cells, 13:1430, Aug 2024. URL: https://doi.org/10.3390/cells13171430, doi:10.3390/cells13171430. This article has 4 citations.

10. (meggiolaro2024metabolomicprofilingof pages 4-5): Leonardo Meggiolaro, Laura Moschino, Matteo Stocchero, Giuseppe Giordano, Vladimiro Vida, Giovanni Di Salvo, and Eugenio Baraldi. Metabolomic profiling of infants undergoing cardiopulmonary bypass and association with clinical outcomes: a systematic review. Frontiers in Cardiovascular Medicine, Nov 2024. URL: https://doi.org/10.3389/fcvm.2024.1491046, doi:10.3389/fcvm.2024.1491046. This article has 4 citations and is from a peer-reviewed journal.

11. (NCT06611787 chunk 1): A Comprehensive Registry Study of the Whole Life Cycle of Patients With CHD. Beijing Anzhen Hospital. 2024. ClinicalTrials.gov Identifier: NCT06611787

12. (salzillo2024cardiovasculardiseasesin pages 15-16): Cecilia Salzillo, Marco La Verde, Amalia Imparato, Rossella Molitierno, Stefano Lucà, Francesca Pagliuca, and Andrea Marzullo. Cardiovascular diseases in public health: chromosomal abnormalities in congenital heart disease causing sudden cardiac death in children. Medicina, 60:1976, Dec 2024. URL: https://doi.org/10.3390/medicina60121976, doi:10.3390/medicina60121976. This article has 15 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.